Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APM NASDAQ:CNSP NASDAQ:ENSC NASDAQ:PTEIQ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPMAptorum Group$1.97+1.5%$1.00$0.46▼$7.49$10.54M-0.171.41 million shs4.20 million shsCNSPCNS Pharmaceuticals$0.90+3.8%$0.99$0.73▼$62.00$4.89M2.581.11 million shs176,164 shsENSCEnsysce Biosciences$2.16$2.21$1.62▼$14.67$5.12M0.98947,261 shs54,202 shsPTEIQPolarityTE$0.15$0.05▼$0.09$1.24M0.9227,292 shs313 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPMAptorum Group+100.04%+115.56%+71.68%+133.37%-54.99%CNSPCNS Pharmaceuticals-0.35%-8.17%+6.44%+5.27%-98.44%ENSCEnsysce Biosciences+2.37%-3.57%+0.47%+22.73%-69.45%PTEIQPolarityTE0.00%0.00%0.00%0.00%-10.53%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPMAptorum Group1.4806 of 5 stars0.05.00.00.02.41.70.6CNSPCNS Pharmaceuticals2.1254 of 5 stars3.34.00.00.02.00.00.6ENSCEnsysce Biosciences0.5891 of 5 stars0.04.00.00.01.90.00.6PTEIQPolarityTEN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPMAptorum Group 0.00N/AN/AN/ACNSPCNS Pharmaceuticals 2.50Moderate Buy$25.002,653.30% UpsideENSCEnsysce Biosciences 0.00N/AN/AN/APTEIQPolarityTE 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PTEIQ, APM, CNSP, and ENSC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025CNSPCNS PharmaceuticalsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPMAptorum Group$430K22.46N/AN/A$2.20 per share0.82CNSPCNS PharmaceuticalsN/AN/AN/AN/A$5.37 per shareN/AENSCEnsysce BiosciencesN/AN/AN/AN/A$2.59 per shareN/APTEIQPolarityTE$810K0.00N/AN/A$2.30 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPMAptorum Group-$4.27MN/A0.00∞N/AN/AN/AN/A7/30/2025 (Estimated)CNSPCNS Pharmaceuticals-$14.86M-$3,748.50N/A∞N/AN/A-385.41%-193.20%8/13/2025 (Estimated)ENSCEnsysce Biosciences-$7.99M-$6.54N/AN/AN/A-109.49%-192.54%-121.77%8/13/2025 (Estimated)PTEIQPolarityTE-$7.83M-$3.28N/AN/AN/AN/A-106.08%-76.91%N/ALatest PTEIQ, APM, CNSP, and ENSC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025ENSCEnsysce Biosciences-$1.02N/AN/AN/A$0.67 millionN/A5/15/2025Q1 2025CNSPCNS PharmaceuticalsN/A-$1.58N/A-$1.58N/AN/A5/13/2025Q1 2025ENSCEnsysce Biosciences-$3.02-$1.39+$1.63-$1.39$0.65 million$1.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPMAptorum GroupN/AN/AN/AN/AN/ACNSPCNS PharmaceuticalsN/AN/AN/AN/AN/AENSCEnsysce BiosciencesN/AN/AN/AN/AN/APTEIQPolarityTEN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPMAptorum GroupN/A0.220.22CNSPCNS PharmaceuticalsN/A4.944.94ENSCEnsysce BiosciencesN/A2.502.50PTEIQPolarityTEN/A4.114.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPMAptorum Group3.80%CNSPCNS Pharmaceuticals14.02%ENSCEnsysce Biosciences5.63%PTEIQPolarityTE11.75%Insider OwnershipCompanyInsider OwnershipAPMAptorum Group63.99%CNSPCNS Pharmaceuticals0.07%ENSCEnsysce Biosciences7.90%PTEIQPolarityTE5.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPMAptorum Group305.35 million1.93 millionNot OptionableCNSPCNS Pharmaceuticals55.46 million5.46 millionNot OptionableENSCEnsysce Biosciences102.37 million2.18 millionNot OptionablePTEIQPolarityTE607.32 million6.99 millionNot OptionablePTEIQ, APM, CNSP, and ENSC HeadlinesRecent News About These CompaniesNo headlines for this company have been tracked by MarketBeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePTEIQ, APM, CNSP, and ENSC Company DescriptionsAptorum Group NASDAQ:APM$1.97 +0.03 (+1.55%) Closing price 04:00 PM EasternExtended Trading$1.89 -0.08 (-4.06%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.CNS Pharmaceuticals NASDAQ:CNSP$0.90 +0.03 (+3.80%) Closing price 04:00 PM EasternExtended Trading$0.90 +0.00 (+0.11%) As of 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.Ensysce Biosciences NASDAQ:ENSC$2.14 -0.02 (-0.69%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.PolarityTE NASDAQ:PTEIQPolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; and other tissue regeneration products. PolarityTE, Inc. is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now Citigroup Earnings Could Signal What’s Next for Markets This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
